Company Filing History:
Years Active: 2010
Title: The Innovations of David Boardman
Introduction
David Boardman is an accomplished inventor based in Norristown, NJ (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of antidiabetic compounds. His work focuses on creating novel crystalline forms that have the potential to improve treatment options for various metabolic disorders.
Latest Patents
David Boardman holds a patent for "Crystalline forms of antidiabetic compounds." This patent describes novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups. These compounds act as selective PPAR gamma partial agonists, which are beneficial in treating type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and metabolic syndrome. The patent includes a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound, along with several crystalline forms of the free acid and the sodium salt of the second compound. Additionally, the invention encompasses pharmaceutical compositions that utilize these novel crystal forms, processes for preparing them, and their applications in treating type 2 diabetes and other PPAR gamma modulated diseases.
Career Highlights
David Boardman is associated with Merck Sharp & Dohme Corp., a leading pharmaceutical company. His work at Merck has allowed him to focus on innovative solutions in drug development, particularly in the area of diabetes treatment. His patent reflects his commitment to advancing medical science and improving patient outcomes.
Collaborations
Throughout his career, David has collaborated with notable colleagues, including Dalian Zhao and Jean-Francois Marcoux. These partnerships have contributed to the success of his research and the development of his patented inventions.
Conclusion
David Boardman's contributions to the field of pharmaceuticals, particularly through his innovative patent on antidiabetic compounds, highlight his role as a significant inventor. His work continues to pave the way for advancements in the treatment of metabolic disorders.